The Queens Cancer Center (QCC) at Queens Hospital Center is dedicated to providing the most advanced and comprehensive care to people who are coping with the disease. The Center is headed by M. Margaret Kemeny, MD. She is one of the few female surgical oncologists in the United States. Among her many distinctions, Dr. Kemeny was most recently recognized as one of the leading surgeons in the metropolitan area by both the Castle Connolly Guide of Top Doctors and New York Magazine. Her career is distinguished by years of innovative clinical and laboratory research. She is world renowned for a technique she developed to treat patients with primary and secondary liver tumors. This method involves localized delivery of chemotherapy through a pump implanted into the hepatic artery. Under Dr. Kemeny's leadership the Queens Cancer Center offers cancer treatment unlike anything previously established in the borough.
Our comprehensive Cancer Center provides a full complement of diagnostic and treatment services for patients. These services begin with cancer prevention and early detection efforts followed by diagnosis, multidisciplinary planning and treatment as well as rehabilitation and support services.
We are committed to unsurpassed cancer care that is delivered with compassion and attention to the dignity of our patients and their loved ones. The new Queens Cancer Center has state-of-the-art medical equipment, including a linear accelerator with a multileaf collimator, 3D planning system, IMRT (intensive modulated radiotherapy), Varian Varis record and verify system and electronic portal imaging, which enables us to provide precise radiation therapy.
Cancer Center offers comprehensive services including:
The Center also provides a host of support programs designed to treat the patient's overall health. Our staff includes experts in pain management, psychiatry, pastoral care, social work and nutrition.
research will be conducted in cancer prevention, early detection, new
drugs and new techniques to treat cancer. The Center is also embarking
on clinical trials such as, a national breast cancer prevention trial
(STAR), testing the effectiveness of Tamoxifen versus Raloxifene in
breast cancer prevention. QCC also is also a site for the national prostate
prevention trial (Select) and the multiple new chemotherapeutic agent